Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07088926 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
A Phase 2 study of Bronchiectasis With Pseudomonas Aeruginosa Colonization, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 435
- Enrollment target
- 20
- Study locations
NCT07088926 is a Phase 2 study of Bronchiectasis With Pseudomonas Aeruginosa Colonization that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 435 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT07088926, a Phase 2 study of Bronchiectasis With Pseudomonas Aeruginosa Colonization, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 435 participants
- Enrollment target
- 20
- Study locations
Study Summary
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AZD0292
Study Locations (20)
Florida
- Research Site - Jacksonville
- Research Site - Miami Lakes
- Research Site - Naples
- Research Site - Ormond Beach
- Research Site - Plantation
California
- Research Site - Orange
- Research Site - San Francisco
Pennsylvania
- Research Site - DuBois
- Research Site - Philadelphia
Colorado
- Research Site - Denver
District of Columbia
- Research Site - Washington D.C.
Georgia
- Research Site - Rincon
Kansas
- Research Site - Kansas City
Michigan
- Research Site - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 435 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07088926
The ClinicalTrials.gov registry entry for NCT07088926 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bronchiectasis With Pseudomonas Aeruginosa Colonization appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07088926 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07088926 about?
NCT07088926 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization". AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
What is the current status of trial NCT07088926?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 435 participants. The study started on 2025-11-06. Estimated completion is 2028-06-14.
What conditions does trial NCT07088926 study?
This clinical trial studies the following conditions: Bronchiectasis With Pseudomonas Aeruginosa Colonization.
What interventions are being tested in trial NCT07088926?
The interventions under investigation include: Placebo (OTHER), AZD0292 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07088926?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07088926 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.